Table 1

Clinical characteristics of six patients with rheumatoid arthritis with confirmed SARS-CoV-2 infection

Patient	1	2	3	4	5	6
Age, years	65	79	62	76	70	71
Gender	Female	Male	Male	Male	Female	Female
Disease duration, years	33	11	12	26	15	11
RF/ACPA	Pos/Pos	Neg/Neg	Neg/Neg	Neg/Pos	Pos/Neg	Pos/Pos
csDMARD	MTX	MTX	LFM	–	MTX	–
bDMARD	Etanercept	–	Golimumab	Adalimumab	Adalimumab	Abatacept
cs/bDMARDs suspended	Yes	No	Yes	No	Yes	No
Prednisone, mg/day	–	7.5	5	–	5	5
BMI	30	27	25.4	25.7	26.8	27.5
Smoke	No	No	No	No	No	Yes
Comorbidity	Diabetes	Hypertension Atrial fibrillation	Dyslipidaemia	Hypertension Diabetes Dyslipidaemia	Hypertension	Hypertension
10-year CV risk SCORE (%)	8	5	0.5	1.5	0.5	1.5
Nasopharyngeal swab	Pos	Pos	Pos	Pos	Pos	Pos
IgG SARS-CoV-2	NA	Pos	Pos	Pos	Pos	NA
Infection symptoms	Fever Anosmia Arthralgia Rhinorrhea Diarrhoea	Fever Heartburn	Fever Non-productive cough Diarrhoea Headache	Asymptomatic (contact with a positive relative)	Fever Fatigue Arthralgia/Myalgia Anosmia Dyspnoea at rest	Fever Dyspnoea at rest Non-productive cough
Pneumonia at chest X-ray	No	No	Yes	No	Yes	No
Respiratory failure	No	No	No	No	No	No
Hospitalisation	No	Yes	Yes	No	Yes	No
PaO₂/FiO₂ ratio PaO₂ at BGA (mm Hg) O₂ saturation (%)	–	423 88 97	414 87 97	–	410 86 96	–
SARS-CoV-2 treatment	None	None	HCQ Azithromycin	None	HCQ Azithromycin	HCQ
Outcome	Healing	Healing	Healing	Healing	Healing	Healing
Time to discharge, days	–	16	9	–	14	–

ACPA, anti-citrullinated protein antibodies; b, biological; BGA, blood gas analysis; cs, conventional synthetic; CV, cardiovascular; DMARDs, disease modifying antirheumatic drug; HCQ, hydroxychloroquine; Neg, negative; O₂, oxygen; Pos, positive; RF, rheumatoid factor; SCORE, Systematic COronary Risk Evaluation.